Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096473
Status:
COMPLETED
Last Update Posted:
2011-04-01
First Post:
2004-11-09
Brief Title:
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimers Disease
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A 24 Week Multicenter Randomized Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride E2020 in Patients With Severe Alzheimers Disease Followed by a 12 Week Open-Label Extension Period
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Donepezil hydrochloride Aricept has been approved to treat symptoms associated with mild to moderate Alzheimers disease AD Aricept has been shown to improve the memory and thinking abilities activities of daily living and global function in patients The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimers disease
Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine This chemical helps a persons memory to work better
Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine This chemical helps a persons memory to work better
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None